Literature DB >> 30248168

The Diagnosis and Management of Retroperitoneal Sarcoma.

Sinziana Dumitra, Alessandro Gronchi.   

Abstract

Retroperitoneal sarcoma (RPS) is a rare tumor whose diagnosis and management can be challenging and for which management requires a multidisciplinary team in a specialized center. An important part of the diagnosis-identification of the histologic subtype-depends on pathology; identifying the histologic subtype is important because this can affect prognosis and treatment options. Complete surgical resection with negative margins remains the cornerstone of treatment of nonmetastatic RPS and is the only chance for cure. In order to achieve negative margins, multivisceral en bloc resection is often necessary. Neoadjuvant therapies (chemotherapy, external beam radiation, or combination radiation and chemotherapy) are safe in well-selected patients and may be considered after careful review by a multidisciplinary sarcoma tumor board when the recurrence risk is high.

Entities:  

Mesh:

Year:  2018        PMID: 30248168

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  7 in total

1.  The Role of Surgical Expertise and Surgical Access in Retroperitoneal Sarcoma Resection - A Retrospective Study.

Authors:  P Aeschbacher; A Kollár; D Candinas; G Beldi; A Lachenmayer
Journal:  Front Surg       Date:  2022-05-12

2.  Neoadjuvant radiotherapy followed by surgery compared with surgery alone in the treatment of retroperitoneal sarcoma: a population-based comparison.

Authors:  B T Turner; L Hampton; D Schiller; L A Mack; C Robertson-More; H Li; M L Quan; A Bouchard-Fortier
Journal:  Curr Oncol       Date:  2019-12-01       Impact factor: 3.677

3.  Transcriptome analysis of tumor-derived mesenchymal progenitor cells shows that CHST15 is a fibrosis regulator of retroperitoneal liposarcoma.

Authors:  Yang Sun; Fengjun Xiao; Huiyan Sun; Lin Zhang; Weida Chen; Li Du; Chengfeng Sun; Weiyuan Zhang; Qinqin Xu; Chengli Miao; Lisheng Wang
Journal:  Ann Transl Med       Date:  2022-03

4.  Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.

Authors:  Chang Xu; Liang Yan; Qiming An; Sha Zhang; Xiaoya Guan; Zhen Wang; Ang Lv; Daoning Liu; Faqiang Liu; Bin Dong; Min Zhao; Xiuyun Tian; Chunyi Hao
Journal:  Int J Med Sci       Date:  2022-07-11       Impact factor: 3.642

5.  Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma.

Authors:  Chang Xu; Liang Yan; Xiaoya Guan; Zhen Wang; Jianhui Wu; Ang Lv; Daoning Liu; Faqiang Liu; Bin Dong; Min Zhao; Ling Jia; Xiuyun Tian; Chunyi Hao
Journal:  Int J Biol Sci       Date:  2022-08-01       Impact factor: 10.750

6.  Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.

Authors:  Liang Yan; Zhen Wang; Can Cui; Xiaoya Guan; Bin Dong; Min Zhao; Jianhui Wu; Xiuyun Tian; Chunyi Hao
Journal:  Cancer Sci       Date:  2019-08-29       Impact factor: 6.716

7.  Retroperitoneal liposarcoma in a nonagenarian.

Authors:  King Tung Cheung; Catherine Mitchell; Enoch Wong
Journal:  Autops Case Rep       Date:  2020-12-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.